The Government is funding Genomic Medicine Sweden (GMS) with SEK 80 million in 2025. The special support will be used, among other things, for continued investments in the sustainable development and implementation of precision medicine in cancer care. Richard Rosenquist Brandell, professor at KI and director of GMS, describes the initiative as an important investment in the future of healthcare.
The grant from the Government strengthens GMS's national work and ensures long-term sustainable development. All with the aim of further developing precision diagnostics and implementing it in practice so that more patients, regardless of where in the country they live, have access to more accurate and equal care.
"This is a powerful recognition of the work being done today within Genomic Medicine Sweden, and an important investment in precision health for the future of healthcare," says Richard Rosenquist Brandell, professor at the Department of Molecular Medicine and Surgery , Karolinska Institutet, and director of Genomic Medicine Sweden (GMS).
Among other things, GMS receives support for work on a national implementation project of whole genome sequencing for rare health conditions, continued work on the implementation of precision-based diagnostics in cancer, and for work on implementing precision diagnostics in infectious diseases, including the detection of antibiotic resistance.
Last year, the Government provided funding of SEK 49.5 million to GMS through the National Board of Health and Welfare. This year, the special support will be increased to SEK 80 million.
"This gives us the opportunity to continue our hard work in developing and introducing precision medicine in a sustainable way in healthcare. This is a true team effort, both between the partners in the GMS and with the many other actors we work with in Sweden," says Richard Rosenquist Brandell.
Allocation of funds
- SEK 4.9 million will be used to continue work on the BrainChild innovation project.
- SEK 14.5 million may be used for work on a national implementation project of whole genome sequencing for rare health conditions based on long DNA reads. The funds may also be used for national and international work on precision diagnostics for children with undiagnosed rare health conditions with malformations and/or intellectual disabilities.
- SEK 6.3 million may be used for continued work on national implementation of whole genome and transcription sequencing for adults with acute leukaemia and for the development of gene panel analysis for sensitive detection of residual disease.
- SEK 19.5 million may be used for scaled-up implementation and further development of precision diagnostics (tissue and liquid biopsies) for solid tumours in routine healthcare and for clinical studies.
- SEK 4.8 million may be used for continued work on implementing precision diagnostics in infectious diseases, including the detection of antibiotic resistance, and for increased data sharing between regions for the detection of outbreaks of antibiotic-resistant bacteria.
- SEK 30 million may be used for the management of the collaborative project that constitutes GMS and which promotes the equal implementation of precision health in the country.
Genomic Medicine Sweden
Genomic Medicine Sweden (GMS) is a national collaboration that includes the seven regions with university hospitals and the seven universities with medical faculties in Gothenburg, Linköping, Lund, Stockholm, Umeå, Uppsala and Örebro.
GMS also collaborates with healthcare, academia, industry, patient organisations and other societal stakeholders such as SciLifeLab .
GMS's goal is to enable improved diagnostics, personalised treatment choices and research in the field of precision medicine through broad collaboration.
